Important COVID-19 Information for Patients. READ NOW
Now Offering Phone and Video Appointments
Ho Lun Wong, PhD, BScPharm
About
Research Profile
Research Program
Research Interests
- Hybrid or lipid-based nanotechnology: Design, evaluation and optimization of lipidpolymer hybrid nanocarriers or lipid-based nanocarriers for sustained, controlled and targeted delivery of therapeutic oligonucleotides (e.g. RNAi agents) and small molecule compounds (e.g. poorly water-soluble novel molecules and chemo agents).
- Strategically merging the “old” and “new”: Develop advanced nanomedicine-based therapeutic strategies for novel combination treatment (e.g. chemo-gene; chemomolecular targeting agent) of malignant diseases, with emphasis on drug-resistant, metastatic prostate cancer, breast cancer and ovarian cancer.
Contact Information
School of Pharmacy
Temple University
Research at Fox Chase Cancer Center includes faculty from throughout Temple Health and Temple University, including the Temple School of Engineering, Temple School of Pharmacy and the Lewis Katz School of Medicine.
Contact Information
School of Pharmacy
Temple University
Research at Fox Chase Cancer Center includes faculty from throughout Temple Health and Temple University, including the Temple School of Engineering, Temple School of Pharmacy and the Lewis Katz School of Medicine.
Assistant Professor
Research Program
Research Profile
Research Interests
- Hybrid or lipid-based nanotechnology: Design, evaluation and optimization of lipidpolymer hybrid nanocarriers or lipid-based nanocarriers for sustained, controlled and targeted delivery of therapeutic oligonucleotides (e.g. RNAi agents) and small molecule compounds (e.g. poorly water-soluble novel molecules and chemo agents).
- Strategically merging the “old” and “new”: Develop advanced nanomedicine-based therapeutic strategies for novel combination treatment (e.g. chemo-gene; chemomolecular targeting agent) of malignant diseases, with emphasis on drug-resistant, metastatic prostate cancer, breast cancer and ovarian cancer.